PetMed Express (PETS) Aktienübersicht
PetMed Express, Inc. ist zusammen mit seinen Tochtergesellschaften in den Vereinigten Staaten als Apotheke für Haustiere tätig. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
PETS Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
PetMed Express, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$1.79 |
| 52-Wochen-Hoch | US$4.10 |
| 52-Wochen-Tief | US$1.57 |
| Beta | 0.77 |
| 1 Monat Veränderung | -19.73% |
| 3 Monate Veränderung | -19.73% |
| 1 Jahr Veränderung | -46.73% |
| 3 Jahre Veränderung | -87.28% |
| 5 Jahre Veränderung | -94.74% |
| Veränderung seit IPO | 43.20% |
Aktuelle Nachrichten und Updates
PETS: Rural King Partnership And Board Review Will Support Future Upside
Analysts have adjusted their price target for PetMed Express to reflect updated views on revenue growth, profit margins, and a future P/E of 12.41. This has led to a revised valuation that aligns more closely with their current earnings expectations for the stock.PETS: Rural King White Label Pharmacy Will Support Future Margin Upside
Analysts have kept their price target on PetMed Express effectively unchanged at about $2.15, reflecting only very small tweaks to inputs such as discount rate, expected revenue trend, profit margin and future P/E assumptions. What's in the News PetMed Express announced a partnership with Rural King to launch a pet pharmacy service across Rural King retail stores and digital platforms, offering prescription medications, preventatives and other pet health products.PetMed Express: High-Risk Turnaround, Hidden Assets, Activism
Summary PetMed Express’ current valuation suggests investors are pricing in a significant deterioration in the franchise. Execution risk is substantial. The assets provide downside support - although continued operating losses will reduce that support. Ultimately, the investment case depends less on asset values and more on on whether management can stabilize revenue and translate operational improvements into earnings. PETS is more of an asset-backed special situation than an operational turnaround. Read the full article on Seeking AlphaRecent updates
PETS: Rural King Partnership And Board Review Will Support Future Upside
Analysts have adjusted their price target for PetMed Express to reflect updated views on revenue growth, profit margins, and a future P/E of 12.41. This has led to a revised valuation that aligns more closely with their current earnings expectations for the stock.PETS: Rural King White Label Pharmacy Will Support Future Margin Upside
Analysts have kept their price target on PetMed Express effectively unchanged at about $2.15, reflecting only very small tweaks to inputs such as discount rate, expected revenue trend, profit margin and future P/E assumptions. What's in the News PetMed Express announced a partnership with Rural King to launch a pet pharmacy service across Rural King retail stores and digital platforms, offering prescription medications, preventatives and other pet health products.PetMed Express: High-Risk Turnaround, Hidden Assets, Activism
Summary PetMed Express’ current valuation suggests investors are pricing in a significant deterioration in the franchise. Execution risk is substantial. The assets provide downside support - although continued operating losses will reduce that support. Ultimately, the investment case depends less on asset values and more on on whether management can stabilize revenue and translate operational improvements into earnings. PETS is more of an asset-backed special situation than an operational turnaround. Read the full article on Seeking AlphaPETS: Rural King Partnership Will Shape Future Margins And Earnings Outlook
Analysts have slightly reduced their price target on PetMed Express, attributing the change to a marginally lower discount rate and a modest increase in the assumed future P/E multiple as the main factors behind the revised outlook. What's in the News PetMed Express announced a partnership with Rural King to launch a new pet pharmacy offering across Rural King’s retail stores and digital platforms, focusing on prescription medications, preventatives and broader pet health products (Key Developments).PETS: Rural King Partnership Will Shape Future Margins And Earnings Multiple
Analysts have trimmed their price target on PetMed Express to reflect a fair value update from $3.00 to $2.15 as they incorporate more moderate expectations for revenue contraction, profit margins, and a higher future P/E multiple into their models. What's in the News PetMed Express announced a partnership with Rural King to launch a new pet pharmacy offering across Rural King retail stores and digital platforms, expanding access to prescription medications, preventatives and pet health products for Rural King customers (Key Developments).Getting In Cheap On PetMed Express, Inc. (NASDAQ:PETS) Is Unlikely
It's not a stretch to say that PetMed Express, Inc.'s ( NASDAQ:PETS ) price-to-sales (or "P/S") ratio of 0.3x right now...Some Confidence Is Lacking In PetMed Express, Inc. (NASDAQ:PETS) As Shares Slide 26%
To the annoyance of some shareholders, PetMed Express, Inc. ( NASDAQ:PETS ) shares are down a considerable 26% in the...
Cost Cuts And Digital Upgrades Will Strain Future Margins
Optimism regarding savings from PetCareRx integration could jeopardize future profitability if anticipated savings do not materialize.PetMed Express: Dip Or Rip, A Buy After Earnings
Summary PetMed Express stock could surge or sink after this week's quarterly earnings release, but don't read too much into this near-term event. A disappointing earnings release won't necessarily shatter the bull case, and could, in fact, push this stock back down to "back up the truck" price levels. Conversely, even if PETS rallies on strong results, this may not capture all of the potential long-term upside. Even if it takes time to take shape, improvements in PetMed's operating performance could ultimately send the stock back to prices north of $15 per share. Read the full article on Seeking AlphaWe Think PetMed Express (NASDAQ:PETS) Can Easily Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Some PetMed Express, Inc. (NASDAQ:PETS) Shareholders Look For Exit As Shares Take 28% Pounding
PetMed Express, Inc. ( NASDAQ:PETS ) shares have retraced a considerable 28% in the last month, reversing a fair amount...PetMed Express: Why (And Why Not) The Rebound Could Continue
Summary PetMed Express (PETS) surged 35.8% on Nov. 7, following the online pet pharmacy's latest quarterly earnings release. Despite the massive post-earnings surge, further upside may lie ahead, if the turnaround continues. PetMed's management team is implementing a strategy change, not just cost-cutting measures, to continue improving the company's fiscal performance. Although many risks and uncertainties remain, given the outsized impact further improvements could have on the PETS stock price, at the very least add it to your watchlist. Read the full article on Seeking AlphaOptimistic Investors Push PetMed Express, Inc. (NASDAQ:PETS) Shares Up 28% But Growth Is Lacking
PetMed Express, Inc. ( NASDAQ:PETS ) shares have had a really impressive month, gaining 28% after a shaky period...PetMed Express, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
There's been a notable change in appetite for PetMed Express, Inc. ( NASDAQ:PETS ) shares in the week since its...PetMed Express, Inc. (NASDAQ:PETS) Just Reported And Analysts Have Been Cutting Their Estimates
PetMed Express, Inc. ( NASDAQ:PETS ) last week reported its latest annual results, which makes it a good time for...PetMed Express, Inc.'s (NASDAQ:PETS) Intrinsic Value Is Potentially 69% Above Its Share Price
Key Insights Using the Dividend Discount Model, PetMed Express fair value estimate is US$7.95 Current share price of...A Look At The Fair Value Of PetMed Express, Inc. (NASDAQ:PETS)
Key Insights PetMed Express' estimated fair value is US$11.85 based on 2 Stage Free Cash Flow to Equity Current share...PetMed Express (NASDAQ:PETS) Is Paying Out A Dividend Of $0.30
The board of PetMed Express, Inc. ( NASDAQ:PETS ) has announced that it will pay a dividend of $0.30 per share on the...Aktionärsrenditen
| PETS | US Specialty Retail | US Markt | |
|---|---|---|---|
| 7D | 2.3% | 3.3% | -2.5% |
| 1Y | -46.7% | 8.7% | 20.1% |
Rendite im Vergleich zur Industrie: PETS unter dem Niveau der Branche US Specialty Retail , die im vergangenen Jahr eine Rendite von 8.7% erzielte.
Rendite vs. Markt: PETS hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 20.1 erzielte.
Preisvolatilität
| PETS volatility | |
|---|---|
| PETS Average Weekly Movement | 7.0% |
| Specialty Retail Industry Average Movement | 7.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: PETS hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: PETSDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 14% auf 7% zurückgegangen.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1996 | 189 | Leslie C. Campbell | www.1800petmeds.com |
PetMed Express, Inc. ist zusammen mit seinen Tochtergesellschaften als Apotheke für Haustiere in den Vereinigten Staaten tätig. Das Unternehmen vertreibt verschreibungspflichtige und nicht verschreibungspflichtige Tierarzneimittel, Gesundheitsprodukte und anderen Bedarf für Hunde, Katzen und Pferde. Es bietet nicht verschreibungspflichtige Medikamente und Zubehör wie Floh- und Zeckenschutzmittel, Knochen- und Gelenkpflegeprodukte, Vitamine, Leckerlis, Nahrungsergänzungsmittel, Hygieneprodukte und Haustierbedarf sowie verschreibungspflichtige Medikamente wie Herzwurm-, Floh- und Zeckenschutzmittel, Arthritis-, Dermatitis-, Schilddrüsen-, Diabetes-, Schmerz-, Herz-/Blutdruck- und andere Spezialmedikamente sowie generische Ersatzpräparate.
PetMed Express, Inc.'s Grundlagenzusammenfassung
| PETS grundlegende Statistiken | |
|---|---|
| Marktanteil | US$37.64m |
| Gewinn(TTM) | -US$57.29m |
| Umsatz(TTM) | US$179.02m |
Ist PETS zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| PETS Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$179.02m |
| Kosten der Einnahmen | US$128.81m |
| Bruttogewinn | US$50.22m |
| Sonstige Ausgaben | US$107.50m |
| Gewinn | -US$57.29m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -2.72 |
| Bruttomarge | 28.05% |
| Nettogewinnspanne | -32.00% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich PETS auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/25 18:21 |
| Aktienkurs zum Tagesende | 2026/06/24 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
PetMed Express, Inc. wird von 15 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Erin Wilson Wright | BofA Global Research |
| Kristine Koerber | Citizens JMP Securities, LLC |
| David Westenberg | CL King & Associates, Inc. |